Technical Analysis for AVXT - Avax Techs Inc

Grade Last Price % Change Price Change
grade C 0.0012 0.00% 0.0000
AVXT closed unchanged on Monday, November 11, 2019, on 31 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AVXT trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish 0.00%
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Doji - Bearish? Reversal 0.00%

Older signals for AVXT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AVAX Technologies, Inc. is a biotechnology company. The Company is focused on developing and commercializing its Autologous Cell (AC) Vaccine Technology Platform for the treatment of cancer. The AC Vaccine is a platform technology, which allows a patient's immune system to recognize its own cancer cells as foreign through the process of haptenization, cell processing and regimen of administration. The Company has approximately two vaccines that have completed Phase II clinical trials, both designated with Orphan Drug Status. MVAX is a post-surgical autologous cell vaccine for melanoma, which was approved to enter a Phase III-REGISTRATION trial for the treatment of Stage IV melanoma patients with measurable metastasis. OVAX is the Company's post-surgical autologous cell vaccine for Stage III and IV ovarian cancer. The OVAX trial is a Phase I/II trial that has completed enrollment and is in the process of gathering follow-up data on all patients.
Medicine Biotechnology Medical Specialties RTT Cancer Treatment Of Cancer Ovarian Cancer Melanoma Vaccines Platform Technology Cancer Vaccine Tumor Antigen Vaccine
Is AVXT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.003
52 Week Low 0.0001
Average Volume 146,840
200-Day Moving Average 0.0013
50-Day Moving Average 0.0014
20-Day Moving Average 0.0014
10-Day Moving Average 0.0015
Average True Range 0.0007
ADX 29.01
+DI 52.0
-DI 25.3333
Chandelier Exit (Long, 3 ATRs ) 0.0009
Chandelier Exit (Short, 3 ATRs ) 0.0031
Upper Bollinger Band 0.0022
Lower Bollinger Band 0.0006
Percent B (%b) 0.38
BandWidth 114.285714
MACD Line -0.0001
MACD Signal Line -0.0001
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0018
Resistance 3 (R3) 0.0019 0.0017 0.0017
Resistance 2 (R2) 0.0017 0.0016 0.0017 0.0017
Resistance 1 (R1) 0.0015 0.0015 0.0014 0.0014 0.0016
Pivot Point 0.0013 0.0013 0.0013 0.0013 0.0013
Support 1 (S1) 0.0011 0.0012 0.0010 0.0010 0.0008
Support 2 (S2) 0.0009 0.0011 0.0009 0.0007
Support 3 (S3) 0.0007 0.0009 0.0007
Support 4 (S4) 0.0006